Last reviewed · How we verify
Clopidogrel+acetylsalicylic acid
This combination inhibits platelet aggregation through two complementary pathways: clopidogrel blocks ADP-mediated platelet activation while acetylsalicylic acid inhibits thromboxane A2 synthesis.
This combination inhibits platelet aggregation through two complementary pathways: clopidogrel blocks ADP-mediated platelet activation while acetylsalicylic acid inhibits thromboxane A2 synthesis. Used for Acute coronary syndrome, Secondary prevention of cardiovascular events post-percutaneous coronary intervention, Stroke prevention in patients with acute ischemic stroke or transient ischemic attack.
At a glance
| Generic name | Clopidogrel+acetylsalicylic acid |
|---|---|
| Also known as | Plavix |
| Sponsor | Rigshospitalet, Denmark |
| Drug class | Dual antiplatelet agent |
| Target | P2Y12 receptor (clopidogrel); cyclooxygenase (acetylsalicylic acid) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Clopidogrel is a P2Y12 receptor antagonist that prevents ADP-induced platelet activation and aggregation. Acetylsalicylic acid (aspirin) irreversibly inhibits cyclooxygenase, blocking thromboxane A2 production and platelet activation. Together, dual antiplatelet therapy provides synergistic inhibition of platelet function through distinct mechanisms, reducing thrombotic events.
Approved indications
- Acute coronary syndrome
- Secondary prevention of cardiovascular events post-percutaneous coronary intervention
- Stroke prevention in patients with acute ischemic stroke or transient ischemic attack
Common side effects
- Bleeding
- Dyspepsia
- Gastrointestinal hemorrhage
- Headache
- Rash
Key clinical trials
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia (PHASE4)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- SIMPLAAFY Clinical Trial (NA)
- INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clopidogrel+acetylsalicylic acid CI brief — competitive landscape report
- Clopidogrel+acetylsalicylic acid updates RSS · CI watch RSS
- Rigshospitalet, Denmark portfolio CI